CervoMed Inc. – Filings and Transcripts

NASDAQ: CRVO
Share price (9/22/26): $2.53
Market cap (9/22/26): $38.3 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement

Shelf registration

Prospectus supplement for primary offering

Registration of securities for employees

Ownership Filter

CVI Investments, Inc.

Ra Capital Management, L.P.

Armistice Capital, LLC

Woodline Partners LP

News Filter

Announces Initial Results From the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia With Lewy Bodies

Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia With Lewy Bodies

Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

Proxies Filter

Definitive proxy

Definitive proxy

Definitive proxy

Additional info about upcoming vote

Additional info about upcoming vote

Other Filter

Notice of effectiveness

Scanned paper annual report submission

Letter from the SEC

Correspondence with the SEC

Letter from the SEC